|
May 8
|
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
|
|
Mar 20
|
Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 18
|
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
|
|
Mar 6
|
Tango Therapeutics to Participate in Upcoming Investor Conferences
|
|
Mar 5
|
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Jan 5
|
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 4
|
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
|
|
Jan 3
|
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
|
|
Dec 13
|
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%
|
|
Sep 18
|
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
Aug 28
|
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
|